659 results on '"Lee, K.H."'
Search Results
2. OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
3. P2.11-01 A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer
4. OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
5. P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
6. EP07.02-13 Utilization of Real-time MRI-guided Stereotactic Ablative Body Radiotherapy in NSCLC, One Step forward Precise Targeting in Radiotherapy
7. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
8. OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
9. Investigation of the role of pre-existing oxide in the initial degradation mechanism in AlGaN/GaN HEMTs under ON-state stress
10. A longitudinal environmental surveillance study for SARS-CoV-2 from the emergency department of a teaching hospital in Hong Kong
11. The energy spectrum of cosmic rays measured by the Telescope Array using 10 years of fluorescence detector data
12. Modelling of physical systems with a Hopf bifurcation using mechanistic models and machine learning
13. PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L
14. Roles of a strain relaxation and an oxygen vacancy on nanoscale inhomogeneities in VO2 thin film
15. Comparing the efficacy of different methods of faecal microbiota transplantation via oral capsule, oesophagogastroduodenoscopy, colonoscopy, or gastric tube
16. Microstructural characterization of atomized U3Si2 powders with different silicon contents (7.4–7.8 wt%)
17. PP006 The significant role of MAP17 including signal transduction, cell cycle regulation, and cell proliferation and metastasis in gastric cancer
18. 187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer
19. Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update
20. Single Port Robotic Hysterectomy after the Previous Robotic Radical Trachelectomy
21. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
22. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
23. EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
24. 1159P The immune checkpoint inhibitors induced endocrinopathies and their effect on prognosis in advanced non-small cell lung cancer patients
25. EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
26. P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
27. 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)
28. Spray analysis of Palm-Based biodiesel to correlate performance and combustion analysis of a compression ignition engine
29. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
30. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
31. Corrosion effects on the nanotribology of a Ni62Nb38 metallic glass
32. Cyclic behavior of non-seismically detailed full-scale exterior beam-column subassemblies with setback in columns
33. 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
34. Role of Adjuvant Chemoradiotherapy in Perihilar Bile Duct Cancer: A Single Institutional Long-Term Follow Up Analysis
35. Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799
36. P47.08 A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
37. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
38. Flow stress characterization of carbon steel S25C in the temperature range of cold forming with an emphasis on dynamic strain aging
39. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
40. 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
41. Cumulative defect structures for experimentally attainable low thermal conductivity in thermoelectric (Bi,Sb)2Te3 alloys
42. Identification of candidate congenital heart defects biomarkers by applying a random forest approach on DNA methylation data
43. Benzothienopyrimidine decorated dibenzofuran as novel n-type hosts for green phosphorescent organic light-emitting diodes: effects of linking topology
44. Dynamic strain aging of an AISI 1025 steel coil and its relationship with macroscopic responses during the upsetting process
45. Two-channel singlet exciton harvesting for high efficiency fluorescent organic light-emitting diodes using dual thermally activated delayed fluorescence mechanism
46. Atomic-scale chemical mapping of copper dopants in Bi2Te2.7Se0.3 thermoelectric alloy
47. P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
48. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
49. MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
50. P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.